How to buy Hoth Therapeutics stock (HOTH)

Hoth Therapeutics is a biotechnology business based in the US. Hoth Therapeutics shares (HOTH) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.82 – a decrease of 3.2% over the previous week. Hoth Therapeutics employs 2 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Hoth Therapeutics stock

Buy Hoth Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Hoth Therapeutics stock price (NASDAQ: HOTH)

Use our graph to track the performance of HOTH stocks over time.

Hoth Therapeutics shares at a glance

• Key figures

Information last updated 2024-12-11.

Latest market close	$0.82
52-week range	$0.58 - $1.73
50-day moving average more info button	$0.85
200-day moving average more info button	$1.00
Wall St. target price	$4.50
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-1.27

Is it a good time to buy Hoth Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Hoth Therapeutics price performance over time

Historical closes compared with the close of $0.81 from 2024-12-16

1 week (2024-12-10)	-5.26%
1 month (2024-11-18)	2.40%
3 months (2024-09-17)	-24.30%
6 months (2024-06-17)	-12.36%

1 year (2023-12-15)	-32.50%
2 years (2022-12-16)	-76.52%
3 years (2021-12-17)	18.5
5 years (2019-12-17)	105.5

Hoth Therapeutics financials

Gross profit TTM	$0
Return on assets TTM	-46.16%
Return on equity TTM	-83.41%
Profit margin	0%
Book value	$1.09
Market Capitalization more info button	$5.8 million

TTM: trailing 12 months

Hoth Therapeutics share dividends

We're not expecting Hoth Therapeutics to pay a dividend over the next 12 months.

Have Hoth Therapeutics's shares ever split?

Hoth Therapeutics's shares were split on a 1:25 basis on 25 October 2022 . So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Hoth Therapeutics shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for Hoth Therapeutics shares which in turn could have impacted Hoth Therapeutics's share price.

Hoth Therapeutics share price volatility

Over the last 12 months, Hoth Therapeutics's shares have ranged in value from as little as $0.58 up to $1.73. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Hoth Therapeutics's is 0.844. This would suggest that Hoth Therapeutics's shares are less volatile than average (for this exchange).

Hoth Therapeutics overview

Hoth Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; and HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc. ; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.

Frequently asked questions

null
What percentage of Hoth Therapeutics is owned by insiders or institutions?
Currently 0.925% of Hoth Therapeutics shares are held by insiders and 5.309% by institutions. How many people work for Hoth Therapeutics?
Latest data suggests 2 work at Hoth Therapeutics. When does the fiscal year end for Hoth Therapeutics?
Hoth Therapeutics's fiscal year ends in December. Where is Hoth Therapeutics based?
Hoth Therapeutics's address is: 590 Madison Avenue, New York, NY, United States, 10022 What is Hoth Therapeutics's ISIN number?
Hoth Therapeutics's international securities identification number is: US44148G1058 What is Hoth Therapeutics's CUSIP number?
Hoth Therapeutics's Committee on Uniform Securities Identification Procedures number is: 44148G105